By IDSE News Staff
Traditional approaches to developing an HIV vaccine have not worked, largely because HIV mutates rapidly and hides key parts of itself from the immune system.
Now, a new study combining data from two separate phase 1 clinical trials shows that a targeted vaccine strategy can successfully activate early immune responses relevant to HIV. Conducted by an international team led by scientists at IAVI and Scripps Research, the trials included nearly 80 participants from both